These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30007168)

  • 1. An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease.
    Rutigliano G; Stazi M; Arancio O; Watterson DM; Origlia N
    Neurobiol Aging; 2018 Oct; 70():86-91. PubMed ID: 30007168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes.
    Zhou Z; Bachstetter AD; Späni CB; Roy SM; Watterson DM; Van Eldik LJ
    J Neuroinflammation; 2017 Apr; 14(1):75. PubMed ID: 28381303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.
    Roy SM; Grum-Tokars VL; Schavocky JP; Saeed F; Staniszewski A; Teich AF; Arancio O; Bachstetter AD; Webster SJ; Van Eldik LJ; Minasov G; Anderson WF; Pelletier JC; Watterson DM
    ACS Chem Neurosci; 2015 Apr; 6(4):666-80. PubMed ID: 25676389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
    Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM
    J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
    Maphis N; Jiang S; Xu G; Kokiko-Cochran ON; Roy SM; Van Eldik LJ; Watterson DM; Lamb BT; Bhaskar K
    Alzheimers Res Ther; 2016 Dec; 8(1):54. PubMed ID: 27974048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entorhinal Cortex dysfunction can be rescued by inhibition of microglial RAGE in an Alzheimer's disease mouse model.
    Criscuolo C; Fontebasso V; Middei S; Stazi M; Ammassari-Teule M; Yan SS; Origlia N
    Sci Rep; 2017 Feb; 7():42370. PubMed ID: 28205565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exogenous 3-Iodothyronamine Rescues the Entorhinal Cortex from β-Amyloid Toxicity.
    Accorroni A; Rutigliano G; Sabatini M; Frascarelli S; Borsò M; Novelli E; Bandini L; Ghelardoni S; Saba A; Zucchi R; Origlia N
    Thyroid; 2020 Jan; 30(1):147-160. PubMed ID: 31709926
    [No Abstract]   [Full Text] [Related]  

  • 8. Cholecystokinin B receptor agonists alleviates anterograde amnesia in cholecystokinin-deficient and aged Alzheimer's disease mice.
    Zhang N; Sui Y; Jendrichovsky P; Feng H; Shi H; Zhang X; Xu S; Sun W; Zhang H; Chen X; Tortorella MD; He J
    Alzheimers Res Ther; 2024 May; 16(1):109. PubMed ID: 38750512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BDNF prevents amyloid-dependent impairment of LTP in the entorhinal cortex by attenuating p38 MAPK phosphorylation.
    Criscuolo C; Fabiani C; Bonadonna C; Origlia N; Domenici L
    Neurobiol Aging; 2015 Mar; 36(3):1303-9. PubMed ID: 25554494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
    Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
    Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer's mouse model by controlling β-amyloid production.
    Colié S; Sarroca S; Palenzuela R; Garcia I; Matheu A; Corpas R; Dotti CG; Esteban JA; Sanfeliu C; Nebreda AR
    Sci Rep; 2017 Mar; 7():45306. PubMed ID: 28361984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction.
    Watterson DM; Grum-Tokars VL; Roy SM; Schavocky JP; Bradaric BD; Bachstetter AD; Xing B; Dimayuga E; Saeed F; Zhang H; Staniszewski A; Pelletier JC; Minasov G; Anderson WF; Arancio O; Van Eldik LJ
    PLoS One; 2013; 8(6):e66226. PubMed ID: 23840427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entorhinal Cortical Deep Brain Stimulation Rescues Memory Deficits in Both Young and Old Mice Genetically Engineered to Model Alzheimer's Disease.
    Xia F; Yiu A; Stone SSD; Oh S; Lozano AM; Josselyn SA; Frankland PW
    Neuropsychopharmacology; 2017 Dec; 42(13):2493-2503. PubMed ID: 28540926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.
    Alam J; Blackburn K; Patrick D
    J Prev Alzheimers Dis; 2017; 4(4):273-278. PubMed ID: 29181493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglia-Based Phenotypic Screening Identifies a Novel Inhibitor of Neuroinflammation Effective in Alzheimer's Disease Models.
    Zhou W; Zhong G; Fu S; Xie H; Chi T; Li L; Rao X; Zeng S; Xu D; Wang H; Sheng G; Ji X; Liu X; Ji X; Wu D; Zou L; Tortorella M; Zhang K; Hu W
    ACS Chem Neurosci; 2016 Nov; 7(11):1499-1507. PubMed ID: 27504670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
    Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
    Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The P38 mitogen-activated protein kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin-1beta on long-term potentiation in the rat dentate gyrus in vitro.
    Coogan AN; O'Neill LA; O'Connor JJ
    Neuroscience; 1999; 93(1):57-69. PubMed ID: 10430470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic treatments with a 5-HT
    Baranger K; Giannoni P; Girard SD; Girot S; Gaven F; Stephan D; Migliorati M; Khrestchatisky M; Bockaert J; Marchetti-Gauthier E; Rivera S; Claeysen S; Roman FS
    Neuropharmacology; 2017 Nov; 126():128-141. PubMed ID: 28844596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
    Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of post-training infusions of a mitogen-activated protein kinase kinase inhibitor into the hippocampus or entorhinal cortex on short- and long-term retention of inhibitory avoidance.
    Walz R; Roesler R; Barros DM; de Souza MM; Rodrigues C; Sant'Anna MK; Quevedo J; Choi HK; Neto WP; DeDavid e Silva TL; Medina JH; Izquierdo I
    Behav Pharmacol; 1999 Dec; 10(8):723-30. PubMed ID: 10780287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.